YURAK-QON TOMIR TIZIMI KASALLIKLARINING ETIOPATOGENEZI

Authors
  • Xakimov Shaxriyor Madiyor o‘g‘li

    Toshkent Davlat Tibbiyot Universiteti Bakalavr

    Author

  • Asilbek Abdumavlyanov Dilshod o‘g‘li

    Toshkent Davlat Tibbiyot Universiteti Bakalavr

    Author

  • Solijonov Abdulloh Mirsaid o‘g‘li

    Toshkent Davlat Tibbiyot Universiteti Bakalavr

    Author

  • Miryunusov Zafarbek Ravshan o‘g‘li

    Toshkent Davlat Tibbiyot Universiteti Bakalavr

    Author

  • Usmonova Xurshida

    Tibbiy va biologik kimyo kafedrasi , Ilmiy rahbar

    Author

Keywords:
Array
Abstract

Ushbu maqolada global va mintaqaviy sog‘liqni saqlash tizimining dolzarb muammosi — yurak-qon tomir kasalliklarining (YuQTK) zamonaviy etiopatogenezi va genetik asoslari tadqiq etiladi. Tadqiqotda aterosklerozning molekulyar rivojlanish bosqichlari bilan bir qatorda, LDLR, ENaC va SCN5A kabi genlardagi mutatsiyalarning kasallik shakllanishidagi o‘rni tahlil qilingan. Maqolaning o‘ziga xosligi shundaki, unda xavf omillarini kompleks nazorat qilishga qaratilgan "Polipill" strategiyasining tibbiy-biokimyoviy samaradorligi O‘zbekiston populyatsiyasi ehtiyojlari nuqtayi nazaridan asoslab beriladi. Tahlillar shuni ko‘rsatadiki, individual genetik determinantlarni hisobga olgan holda kompleks profilaktika choralarini (Polipill) qo‘llash o‘tkir ishemik xurujlar xavfini 80% dan ortiqroqqa kamaytirish imkonini beradi.

References

1.Wald, N. J., & Law, M. R. (2003). A strategy to reduce cardiovascular disease by more than 80%. BMJ (Clinical research ed.), 326(7404), 1419.

2.https://doi.org/10.1136/bmj.326.7404.1419

3.Yusuf, S., et al. (2021). Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine, 384(3), 216-228.

4.https://www.nejm.org/doi/full/10.1056/NEJMoa2028220

5.Castellano, J. M., et al. (2022). Polypill Strategy in Secondary Cardiovascular Prevention. New England Journal of Medicine, 387(13), 1167-1177.

6.https://www.nejm.org/doi/full/10.1056/NEJMoa2208275

7.Libby, P. (2021). The changing landscape of atherosclerosis. Nature, 592(7855), 524-533.

8.Knowles, J. W., & Ashley, E. A. (2018). Cardiovascular genetics: development and clinical application. European Heart Journal, 39(13), 1083-1093.

9.O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2023). Arterial gipertenziya va yurak-qon tomir xavf omillarini boshqarish bo‘yicha milliy klinik protokol.

10.Roshandel, G., et al. (2019). Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. The Lancet, 394(10199), 672-683.

11.Rader, D. J., & Kathiresan, S. (2021). Genetics of Human Plasma Lipids. Circulation Research, 128(7), 929-951.

12.Pirmohamed, M. (2014). Personalized pharmacogenetics: Outcomes and cost effectiveness. Nature Reviews Genetics, 15(6), 413-424.

Cover Image
Downloads
Published
2026-05-04
Section
Articles